Drug Discovery Services Market Research Explores Growth Within A $39.79 Billion Opportunity

The landscape of drug discovery services is rapidly evolving, driven by technological advancements and increasing demand for efficient pharmaceutical development. This sector is on track for substantial growth, influenced by innovations that streamline the drug discovery process and the rising focus on precision medicine. Let's explore the current market size, key drivers, prominent players, and emerging trends shaping this dynamic field.

Projected Growth and Market Size of Drug Discovery Services
The drug discovery services market is anticipated to experience swift expansion over the coming years. By 2030, the market size is expected to reach $39.79 billion, growing at a compound annual growth rate (CAGR) of 14.4%. Several factors contribute to this strong growth outlook, including the development of precision medicine pipelines, the increasing use of AI-driven discovery platforms, growing investment in biotech startups, research into complex diseases, and the need for accelerated lead optimization. Key trends predicted during this period involve a greater outsourcing of drug discovery tasks, expanded application of AI in target identification, a rise in early-stage discovery services, growing demand for biologics, and the blending of in vitro and in vivo studies to improve efficiency.

The drug discovery services market size has grown rapidly in recent years. It will grow from $20.52 billion in 2025 to $23.21 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to pharmaceutical r&d expansion, cost pressures on drug developers, cro service growth, target-based drug discovery, academic-industry collaborations.

Download a free sample of the drug discovery services market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8324&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Main Drivers Accelerating the Drug Discovery Services Market
The growth of the drug discovery services market is propelled by the rising adoption of precision medicine, which aims to tailor treatments based on individual patient characteristics. This shift is encouraging pharmaceutical companies to seek specialized discovery services that support personalized therapeutic development.
Additionally, the integration of artificial intelligence and machine learning technologies is transforming drug discovery by enabling faster and more accurate identification of potential drug candidates. These tools improve efficiency, reduce costs, and shorten timelines, making drug discovery more productive and cost-effective.

Leading Companies Shaping the Drug Discovery Services Industry
Several key players dominate the drug discovery services market, including Thermo Fisher Scientific Inc., Albany Molecular Research Inc., Charles River Laboratories International Inc., Laboratory Corporation of America Holdings, Domainex Ltd., GenScript Biotech Corporation, Pharmaceutical Product Development LLC, Advinus Therapeutics Pvt. Ltd., Jubilant Biosys Ltd., Evotec AG, Syngene International Ltd., Bayer AG, Merck KGaA, Ubiquigent Ltd., Eurofins Scientific SE, AppTec Laboratory Services Inc., GVK Biosciences Private Limited, Aurigene Discovery Technologies Limited, Viva Biotech Holdings, Pharmaron Beijing Co. Ltd., Selcia Limited, Concept Life Sciences Group Limited, BioDuro LLC, ChemPartner Corporation, Aptuit LLC, Sygnature Discovery Limited, Peak Proteins Ltd., SRI International, BioAscent Discovery Limited, Sai Life Sciences Limited, Promega Corporation, MedChemExpress LLC, Aragen Bioscience Inc., WuXi STA, BioNTech SE, Moderna Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals Inc., Amgen Inc., and Bristol-Myers Squibb Company.

View the full drug discovery services market report:
https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Important Acquisition Boosting Market Presence
In January 2023, Sygnature Discovery, a UK-based integrated drug discovery firm, completed its acquisition of SB Drug Discovery for an undisclosed sum. This strategic move aims to enhance the capabilities and reach of both companies, supporting Sygnature's vision of expanding its integrated drug discovery solutions. SB Drug Discovery specializes in providing critical data for novel drug development through services like cell line generation, assay development, and compound screening.

Innovation and Technological Advances Driving the Market Forward
Cutting-edge technologies such as artificial intelligence (AI) and machine learning (ML) are playing an increasingly vital role in drug discovery services. AI involves computer systems performing tasks typically requiring human intelligence, while ML focuses on algorithms and models that enable machines to learn from data and make predictions.
For example, in February 2024, Eurofins Discovery, a France-based company offering pharmaceutical support services, launched DiscoveryAI SAFIRE. This advanced platform combines proprietary datasets with AI and ML to accelerate drug discovery by predicting key molecular properties related to Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET). The platform builds on Eurofins Discovery's extensive BioPrint database, curated through years of dedicated research, enhancing the accuracy and speed of pharmaceutical development.

Market Segmentation Highlighting the Largest Share in Drug Discovery Services
The drug discovery services market is divided into several segments for a detailed understanding:
1) By Type: Chemistry Services and Biology Services
2) By Process: Target Selection, Target Validation, Hit-to-Lead Identification, Lead Optimization, Candidate Validation
3) By Drug Type: Biologics Drug and Small Molecule Drug
4) By End User: Pharmaceutical and Biotechnology Companies, Academic Institutes, and Other Users

Further subcategories include:
- Chemistry Services: Medicinal Chemistry, Compound Management, High-Throughput Screening, Lead Optimization
- Biology Services: In Vitro Studies, In Vivo Studies, Pharmacokinetics and Pharmacodynamics (PK/PD), Biomarker Discovery

This segmentation provides a comprehensive overview of the market's structure, helping to identify areas with the largest market shares and growth potential.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.